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Abstract
Diabetes Mellitus (DM) is a chronic cardio-metabolic disease and plays 
an important role on cardiovascular outcomes, most importantly when 
associated with an already established heart disease. Its effects in 
the body involve both metabolic and structural changes. To avoid 
such complications, in addition to the strategies already used and 
known, rises the Empaglifozin, a sodium glucose co-transporter inhi-
bitor 2 (SGLT2). Its benefits and efficacy have been tried and tested 
in large-scale trials, with multidimensional cardiovascular effects that 
go beyond the adequate glycemic control. The EMPA-REG Outcome 
materialize such benefits, especially for people at high cardiovascular 
risk, when significantly reduced cardiovascular death and death from 
any cause in this population.
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Type 2 diabetes (T2DM) is a major risk factor for cardiovascular disease 
[1, 2], and the presence of both type 2 diabetes and cardiovascular 
disease increases the risk of death [3]. T2DM is a complex cardio-me-
tabolic disorder characterised by insulin resistance, pancreatic beta-cell 
failure and hyperglycemia [4, 5]. The hyperglycemia plays a critical role 
in the pathogenesis of diabetic complications and in the development 
of hypertension in patients with DM (diabetes mellitus). This is explai-
ned in part through effects on activation of the renin angiotensin 
aldosterone system (RAAS) and sympathetic nervous system (SNS) as 
well as suppression of nitric oxide [6] leading to macrovascular dys-
function including increased arterial stiffness [7, 8]. 
Cardiovascular complications are an important cause of morbidity 
and mortality in patients with diabetes, and endothelial dysfunction is 
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an early indicator of developing cardiovascular com-
plications [9, 10]. Recommended strategies for redu-
cing exacerbate cardiovascular risk in patients with 
T2DM include glucose management, lipid lowering, 
BP (blood pressure) control, smoking cessation, and 
weight loss [11, 12].
Empagliflozin is a novel inhibitor, which has hig-
her selectivity for the sodium glucose cotransporter 
2 (SGLT2) over other SGLT receptors compared with 
other class members [13, 14]. In patients with T2DM, 
inhibition of the SGLT2 increases urinary glucose 
excretion and reduces plasma glucose. Additional 
benefits are weight loss [15] that can lead to impro-
vements in glycemic control [16], and a reduction in 
blood pressure (BP) which is probably attributable 
to osmotic dieresis [17, 18].
Empagliflozin used as monotherapy or add-on 
therapy improved hemoglobin A1c (HbA1c) appro-
ximately 0.7-1.0% -point (depending on baseline 
HbA1c and renal function) with a low risk of hy-
poglycemia, reduced body weight and BP, without 
increases in heart rate, and had small effects on 
plasma lipids (increase in HDL-cholesterol, increase 
in LDL-cholesterol, no change in LDL/HDL choles-
terol ratio) [12, 19, 20]. Besides this, it presented 
favorable effects on markers of arterial stiffness and 
vascular resistance as well as on a marker of myocar-
dial workload [21]. Prospective studies have shown 
an association of blood glucose levels and glycated 
hemoglobin (A1C) with cardiovascular events in dia-
betic and in those patients in the pre-diabetic state, 
with the highest incidence of cardiovascular events 
[22-24]
In another study In Japanese patients with T2DM, 
empagliflozin monotherapy for 52 weeks led to sus-
tained reductions in HbA1c, fasting plasma glucose, 
body weight and Systolic blood pressure; [25-27]. 
Tikkanen et. al noted  that Empagliflozin maintains 
the circadian BP rhythm, with higher reductions in 
daytime versus nighttime BP. Greater reductions in 
BP were observed in patients with a BP ≥130/80 
mmHg (ambulatory blood pressure monitoring) 
compared with those with <130/80 mmHg at ba-
seline, suggesting that the risk of hypotension in 
normotensive patients treated with empagliflozin 
may be low [28].
The mechanisms behind the cardiovascular bene-
fits of empagliflozin are multidimensional [29] and 
possibly involve changes in arterial stiffness [30, 31], 
cardiac function, and cardiac oxygen demand (in 
the absence of sympathetic-nerve activation) [30], 
as well as cardiorenal effects [30, 32-34], reduc-
tion in albuminuria [20, 25], reduction in uric acid 
[19, 20], and established effects on hyperglycemia, 
weight, visceral adiposity, and BP [3].
In international phase III studies, empagliflozin 
10 and 25mg for 24 weeks led to significant im-
provements in glycaemic control and reduced body 
weight and BP in patients with T2DM when given 
as monotherapy [36] add-on to metformin [37], 
add-on to metformin plus sulphonylurea (SU) [19] 
or add-on to pioglitazone with or without metfor-
min [18, 38].
To date, few serious adverse events have been 
reported from clinical trials. The frequency of hy-
poglycaemic events was low, similar to that of pla-
cebo, and lower than comparators known to have 
increased risk of hypoglycaemia, with the choice of 
co-administered glucose-lowering agent being the 
major determinant of hypoglycaemic risk [5, 39] as 
increased incidence of urinary and genital tract in-
fections Among Patients treated with SGLT2 inhi-
bitors, which could potentially be attributed to the 
glycosuria effect of these agents [14, 40, 41].
In the EMPA-REG, among patients with type 2 
diabetes at high risk for cardiovascular events, tho-
se receiving empagliflozin had a lower rate of the 
primary composite outcome of death from cardio-
vascular causes, nonfatal myocardial infarction, or 
nonfatal stroke than did patients receiving placebo. 
The reductions in the risk of cardiovascular death 
in the empagliflozin group were consistent across 
subgroups according to baseline characteristics, re-
presenting the relative reduction of 32% [3].
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Empaglifozin may play an important role in dia-
betics patients. It has not only glycemic effects, but 
lowers blood pressure levels, promotes weight loss, 
and acts in microalbuminuria. All of this would al-
ready be reason to excitement, but EMPA-REG 
outcome showed us, perhaps, the greatest benefit 
that an anti-diabetic oral drug had ever did: the 
consistent cardiovascular benefits found in this trial 
puts empaglifozin in a level no one drug with this 
purposes has. The relative and absolute reduction 
showed in cardiovascular death and death from any 
causes represents strong evidence that among a 
high cardiovascular risk population, this drug might 
be recommended not only for diabetes control, but 
also for death prevention.
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